$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000185173422000752 Filed on December 28, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022
Revenue	$6.261K	$1.570K	$15.65K
YoY Change	33.33%	0.0%	35.34%
Cost Of Revenue	$17.64K	$130.00	$51.49K
YoY Change	5.02%	-99.2%	95.91%
Gross Profit	-$11.37K	$1.440K	-$35.84K
YoY Change	-5.97%	-109.86%	143.51%
Gross Profit Margin	-181.66%	91.72%	-228.96%
Selling, General & Admin	$1.103M	$1.211M	$4.520M
YoY Change	-12.68%	-14.02%	-9.78%
% of Gross Profit		84125.69%
Research & Development	$161.5K	$231.2K	$1.153M
YoY Change	-31.18%	-23.27%	-14.76%
% of Gross Profit		16056.25%
Depreciation & Amortization	$663.00	$800.00	$3.196K
YoY Change	-17.02%	0.0%	23.54%
% of Gross Profit		55.56%
Operating Expenses	$1.264M	$1.443M	$5.673M
YoY Change	-15.58%	-15.65%	-10.84%
Operating Profit	-$1.276M	-$1.441M	-$5.709M
YoY Change	-15.5%	-16.45%	-10.48%
Interest Expense	$524.3K	-$447.4K	$567.0K
YoY Change	1200.09%	1009.3%	276.7%
% of Operating Profit
Other Income/Expense, Net	-$524.3K		$433.0K
YoY Change	1200.09%		216.85%
Pretax Income	-$1.800M	-$1.889M	-$5.276M
YoY Change	16.12%	6.99%	-15.46%
Income Tax
% Of Pretax Income
Net Earnings	-$1.800M	-$1.889M	-$5.276M
YoY Change	16.12%	6.99%	-15.46%
Net Earnings / Revenue	-28750.3%	-120290.45%	-33707.22%
Basic Earnings Per Share	-$1.44		-$0.02
Diluted Earnings Per Share	-$1.44	-$7.582K	-$21.99K
COMMON SHARES
Basic Shares Outstanding	249.9M	249.9M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.62K	$746.9K	$746.9K
YoY Change	-99.02%	-67.05%	-67.05%
Cash & Equivalents	$10.62K	$746.9K
Short-Term Investments
Other Short-Term Assets	$288.9K	$436.4K	$436.4K
YoY Change	-18.44%	42.0%	42.0%
Inventory	$1.412M	$1.415M	$1.415M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.711M	$2.598M	$2.598M
YoY Change	-32.52%	-29.16%	-29.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.381K	$2.044K	$2.040K
YoY Change	-68.9%	-60.99%	-61.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.500K	$3.500K	$3.500K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$4.881K	$5.544K	$5.540K
YoY Change	-38.53%	-36.57%	-36.61%
TOTAL ASSETS
Total Short-Term Assets	$1.711M	$2.598M	$2.598M
Total Long-Term Assets	$4.881K	$5.544K	$5.540K
Total Assets	$1.716M	$2.604M	$2.604M
YoY Change	-32.54%	-29.18%	-29.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.761M	$1.328M	$1.328M
YoY Change	135.22%	225.42%	225.43%
Accrued Expenses	$493.7K	$446.3K	$446.3K
YoY Change	142.58%	39.7%	39.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.000M	$550.0K	$550.0K
YoY Change
Total Short-Term Liabilities	$4.145M	$3.320M	$3.320M
YoY Change	112.31%	92.21%	92.21%
LONG-TERM LIABILITIES
Long-Term Debt	$2.754M	$2.812M	$2.812M
YoY Change	72.13%	75.77%	75.77%
Other Long-Term Liabilities	$705.7K	$663.8K	$663.8K
YoY Change	-50.13%	-51.71%	-51.71%
Total Long-Term Liabilities	$3.460M	$3.476M	$3.476M
YoY Change	14.75%	16.86%	16.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.145M	$3.320M	$3.320M
Total Long-Term Liabilities	$3.460M	$3.476M	$3.476M
Total Liabilities	$7.605M	$6.797M	$6.797M
YoY Change	53.1%	44.54%	44.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.87M	-$55.07M
YoY Change	10.76%	10.59%
Common Stock	$50.98M	$50.88M
YoY Change	21430.86%	4.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.889M	-$4.193M	-$4.193M
YoY Change
Total Liabilities & Shareholders Equity	$1.716M	$2.604M	$2.604M
YoY Change	-32.54%	-29.18%	-29.18%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022
OPERATING ACTIVITIES
Net Income	-$1.800M	-$1.889M	-$5.276M
YoY Change	16.12%	6.99%	-15.46%
Depreciation, Depletion And Amortization	$663.00	$800.00	$3.196K
YoY Change	-17.02%	0.0%	23.54%
Cash From Operating Activities	-$650.1K	-$1.669M	-$4.456M
YoY Change	-44.84%	10.37%	-25.22%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$86.26K	2.361M	$2.936M
YoY Change			-59.61%
NET CHANGE
Cash From Operating Activities	-$650.1K	-1.669M	-$4.456M
Cash From Investing Activities		0.000	$0.00
Cash From Financing Activities	-$86.26K	2.361M	$2.936M
Net Change In Cash	-$736.3K	691.9K	-$1.520M
YoY Change	-37.52%	-145.75%	-216.24%
FREE CASH FLOW
Cash From Operating Activities	-$650.1K	-$1.669M	-$4.456M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$1.669M	-$4.456M
YoY Change		10.37%	-25.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	748275	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3320494	usd
CY2022Q3	us-gaap	Assets Assets	2603739	usd
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	8740	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001537561
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Life Insurance EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLifeInsurance	0	pure
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-54986
CY2022	dei	Entity Registrant Name EntityRegistrantName	ARCH THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-0524102
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	235 Walnut Street, Suite 6
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Framingham
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01702
CY2022	dei	City Area Code CityAreaCode	617
CY2022	dei	Local Phone Number LocalPhoneNumber	431-2313
CY2022	dei	Security12g Title Security12gTitle	Common Stock, par value $0.001 per share
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Entity Public Float EntityPublicFloat	22000000	usd
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	249936370
CY2022	dei	Auditor Firm AuditorFirmId	23
CY2022	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2022	dei	Auditor Location AuditorLocation	Tewksbury, Massachusetts
CY2022Q3	us-gaap	Cash Cash	746940	usd
CY2021Q3	us-gaap	Cash Cash	2266639	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1414848	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	1093765	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	436407	usd
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	307341	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	2598195	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	3667745	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2044	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5240	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3500	usd
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3500	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	5544	usd
CY2021Q3	us-gaap	Assets Assets	3676485	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1328000	usd
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	408083	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	318505	usd
CY2021Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	319464	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	550000	usd
CY2021Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	127781	usd
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2022Q3	arch	Interest Payable Noncurrent InterestPayableNoncurrent	204575	usd
CY2022Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	459200	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3476048	usd
CY2022Q3	us-gaap	Liabilities Liabilities	6796542	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	249886370
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	249936370
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	249886	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	50630084	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55072773	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4192803	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2603739	usd
CY2022	us-gaap	Revenues Revenues	15652	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	51489	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	26282	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4519636	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5009323	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1353084	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5708806	usd
CY2022	us-gaap	Interest Expense InterestExpense	567048	usd
CY2021	us-gaap	Interest Expense InterestExpense	150531	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	178229	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1000000	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	108944	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	432952	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	136642	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5275854	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6240482	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	239914846
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	220001412
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1025674	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5275854	usd
CY2022	arch	Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts	1609141	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	499584	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4192803	usd
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-1500491	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6240482	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	496066	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-1025674	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5275854	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6240482	usd
CY2022	us-gaap	Depreciation Depreciation	3196	usd
CY2021	us-gaap	Depreciation Depreciation	2587	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	499583	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	496066	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1000000	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	108944	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	248073	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	181988	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	302049	usd
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	178229	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	569156	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	307760	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-225124	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	91668	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	846869	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	66033	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	265000	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	151285	usd
CY2022	arch	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	-959	usd
CY2021	arch	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	70496	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4456075	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5958628	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3275	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3275	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	106257	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	-0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1050000	usd
CY2022	arch	Proceeds From Convertible Notes Warrants And Common Stock Net Of Financing Costs ProceedsFromConvertibleNotesWarrantsAndCommonStockNetOfFinancingCosts	3525000	usd
CY2021	arch	Proceeds From Convertible Notes Warrants And Common Stock Net Of Financing Costs ProceedsFromConvertibleNotesWarrantsAndCommonStockNetOfFinancingCosts	0	usd
CY2022	arch	Proceeds From Issuance Of Common Stock And Warrants Net Of Financing Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts	0	usd
CY2021	arch	Proceeds From Issuance Of Common Stock And Warrants Net Of Financing Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfFinancingCosts	6219233	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	482367	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2936376	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7269233	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1519699	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1307330	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2266639	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	959309	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	746940	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2266639	usd
CY2022	arch	Short Term Loan Issued ShortTermLoanIssued	354190	usd
CY2021	arch	Short Term Loan Issued ShortTermLoanIssued	0	usd
CY2022	arch	Issuance Of Restricted Stock IssuanceOfRestrictedStock	8959	usd
CY2021	arch	Issuance Of Restricted Stock IssuanceOfRestrictedStock	0	usd
CY2022	arch	Debt Conversion Converted Debt Amount DebtConversionConvertedDebtAmount	699781	usd
CY2021	arch	Debt Conversion Converted Debt Amount DebtConversionConvertedDebtAmount	0	usd
CY2022	arch	Issuance Of Restricted Stock For Services IssuanceOfRestrictedStockForServices	30840	usd
CY2021	arch	Issuance Of Restricted Stock For Services IssuanceOfRestrictedStockForServices	103750	usd
CY2022	arch	Unpaid Issuance Costs In Accounts Payable UnpaidIssuanceCostsInAccountsPayable	73048	usd
CY2021	arch	Unpaid Issuance Costs In Accounts Payable UnpaidIssuanceCostsInAccountsPayable	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<span style="text-decoration: underline; ">Use of Estimates</span>Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="text-decoration: underline; ">Concentration of Credit Risk</span>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.
CY2021Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	2740	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	162191	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	57812	usd
CY2022Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	70805	usd
CY2021Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	62946	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15631061	usd
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15147957	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15631061	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15147957	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<span style="text-decoration: underline; ">Derivative Liabilities</span>The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, <i>Derivatives and Hedging</i> (“<i>ASC 815</i>”)<i>.</i> Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33756	usd
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33756	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31712	usd
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28516	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2044	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5240	usd
CY2022	us-gaap	Depreciation Depreciation	3196	usd
CY2021	us-gaap	Depreciation Depreciation	2587	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9063	usd
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	249571	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1405785	usd
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	844194	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1414848	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	1093765	usd
CY2016Q3	arch	Shelf Registration Statement Maximum Amount Authorized ShelfRegistrationStatementMaximumAmountAuthorized	50000000	usd
CY2022Q3	us-gaap	Accrued Rent Current And Noncurrent AccruedRentCurrentAndNoncurrent	21000	usd
CY2022Q2	arch	Operating Lease Monthly Rent Payment Obligation OperatingLeaseMonthlyRentPaymentObligation	3500	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	43125004
CY2022Q3	arch	Percentage Of Principal Amount PercentageOfPrincipalAmount	0.15	pure
CY2022Q3	arch	Proceeds From Issuance Of Convertible Notes Common Stock And Warrants Gross ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross	3500000	usd
CY2022Q3	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	775000	usd
CY2022Q3	arch	Placement Agents Fees PlacementAgentsFees	555000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11485524	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10022020	usd
CY2022Q3	arch	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	1535736	usd
CY2021Q3	arch	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	1703849	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	946243	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	946158	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1427946	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2352432	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	2616	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0365	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0580	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Life Insurance EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLifeInsurance	-0.0001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.1810	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0023	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0029	pure
CY2022	arch	Effective Income Tax Rate Reconciliation Nondeductible Expense Fair Value Of Derivative Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueOfDerivativePercent	0.0398	pure
CY2021	arch	Effective Income Tax Rate Reconciliation Nondeductible Expense Fair Value Of Derivative Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueOfDerivativePercent	0.0037	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0060	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0114	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0141	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0916	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2606	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	42695000	usd
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	37018000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	40367000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	36033000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	483000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1626000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7944	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1944	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0013	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0285	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24899014
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y9M29D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	140151	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1325000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.03
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6498818
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.35
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19725196
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y5M15D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16900	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	16504312
CY2022	arch	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	0.29
CY2022	arch	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P1Y6M7D
CY2022	arch	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue	0	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	19725196
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.26
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y5M15D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	16900	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.10
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.13
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.10
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.16
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	-0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.09
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.10
CY2018Q3	us-gaap	Accrued Rent Current And Noncurrent AccruedRentCurrentAndNoncurrent	38400	usd
CY2019Q3	us-gaap	Accrued Rent Current And Noncurrent AccruedRentCurrentAndNoncurrent	39600	usd
CY2020Q3	us-gaap	Accrued Rent Current And Noncurrent AccruedRentCurrentAndNoncurrent	42000	usd
CY2021Q3	us-gaap	Accrued Rent Current And Noncurrent AccruedRentCurrentAndNoncurrent	42000	usd

Files In Submission

Name	View Source	Status
0001851734-22-000752-index-headers.html	Edgar Link	pending
0001851734-22-000752-index.html	Edgar Link	pending
0001851734-22-000752.txt	Edgar Link	pending
0001851734-22-000752-xbrl.zip	Edgar Link	pending
arch-20220930.xsd	Edgar Link	pending
arch20220930_10k.htm	Edgar Link	pending
ex_435289.htm	Edgar Link	pending
ex_435290.htm	Edgar Link	pending
ex_435291.htm	Edgar Link	pending
ex_435292.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
arch-20220930_pre.xml	Edgar Link	unprocessable
arch-20220930_def.xml	Edgar Link	unprocessable
arch-20220930_lab.xml	Edgar Link	unprocessable
arch-20220930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
arch20220930_10k_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2022 Q4 Form 10-K Financial Statement

#000185173422000752 Filed on December 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2022 Q4 Form 10-K Financial Statement

#000185173422000752 Filed on December 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth